2. Metabolic Enzyme/Protease Anti-infection
  3. Cathepsin SARS-CoV
  4. ONO-5334

ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease.

For research use only. We do not sell to patients.

ONO-5334 Chemical Structure

ONO-5334 Chemical Structure

CAS No. : 868273-90-9

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 550 In-stock
Solution
10 mM * 1 mL in DMSO USD 550 In-stock
Solid
5 mg USD 500 In-stock
10 mg USD 800 In-stock
25 mg USD 1760 In-stock
50 mg USD 2640 In-stock
100 mg USD 3960 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

ONO-5334 Related Antibodies

Top Publications Citing Use of Products

View All Cathepsin Isoform Specific Products:

View All Isoforms
Cathepsin B Cathepsin C Cathepsin D Cathepsin E Cathepsin K Cathepsin L Cathepsin S

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease[1].

IC50 & Target

cathepsin K

 

In Vitro

ONO-5334 has inhibitory effects on human cathepsin S, human cathepsin L, human cathepsin B, porcine calpain Ι and porcine calpain II with Ki values of 0.83 nM, 1.7 nM, 32 nM, 82 nM and 69 nM, respectively[1].
ONO-5334 (0.1-1 μM; 24 hours) suppresses human osteoclast-mediated bone resorption. It potently reduces osteoclast-mediated release of CTX from bone slices as a dose dependent manner[1].
ONO-5334 (0-10 μM; pre-treated for 16 h) inhibits antiviral activities in a discernable dose-dependent manner in Vero E6 cells by designed to capture multicycle replication, exhibiting an EC50 value of 0.5 μM[2]/

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ONO-5334 Related Antibodies

Cell Viability Assay[2]

Cell Line: Vero E6 cells
Concentration: 0.001 μM, 0.003 μM, 0.1 μM, 0.3 μM, 1 μM, 2.5 μM
Incubation Time: Pre-treated for 16 h and then cultured for 24 hours
Result: Inhibited SARS-COV-2 virus replication in a dose-dependent manner.
In Vivo

ONO-5334 (oral administration; 0.12-15 mg/kg; single dose) can dose-dependently reduce PTHrP-induced increase in plasma calcium with significant effect (86% reduction) at 15 mg/kg. It also reduces PTHrP-induced increase in plasma CTX level in TPTX rats by 90% at 15 mg/kg[1].
ONO-5334 (oral administration; 0.3-30 mg/kg; 7 consecutive days) at 3 mg/kg or 30 mg/kg significantly decreases CTX (a bone resorption marker) concentration. On day 7, the reduction in serum CTX concentration by ONO-5334 at 3 mg/kg and 30 mg/kg was 62% and 79%, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Monkey[1]
Dosage: 0.3 mg/kg; 3 mg/kg
Administration: Oral administration; 7 consecutive days
Result: Reduced bone resorption markers but not bone formation markers in normal monkeys.
Clinical Trial
Molecular Weight

438.58

Formula

C21H34N4O4S
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(C(N/N=C(SC[C@H]1C)/N1C)=O)[C@H](C2CCOCC2)NC(C3CCCCCC3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (114.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2801 mL 11.4004 mL 22.8009 mL
5 mM 0.4560 mL 2.2801 mL 4.5602 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.83%

COA (249 KB) LCMS (113 KB) Elemental Analysis Report (106 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2801 mL 11.4004 mL 22.8009 mL 57.0021 mL
5 mM 0.4560 mL 2.2801 mL 4.5602 mL 11.4004 mL
10 mM 0.2280 mL 1.1400 mL 2.2801 mL 5.7002 mL
15 mM 0.1520 mL 0.7600 mL 1.5201 mL 3.8001 mL
20 mM 0.1140 mL 0.5700 mL 1.1400 mL 2.8501 mL
25 mM 0.0912 mL 0.4560 mL 0.9120 mL 2.2801 mL
30 mM 0.0760 mL 0.3800 mL 0.7600 mL 1.9001 mL
40 mM 0.0570 mL 0.2850 mL 0.5700 mL 1.4251 mL
50 mM 0.0456 mL 0.2280 mL 0.4560 mL 1.1400 mL
60 mM 0.0380 mL 0.1900 mL 0.3800 mL 0.9500 mL
80 mM 0.0285 mL 0.1425 mL 0.2850 mL 0.7125 mL
100 mM 0.0228 mL 0.1140 mL 0.2280 mL 0.5700 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ONO-5334 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ONO-5334868273-90-9ONO5334ONO 5334CathepsinSARS-CoVSARS coronaviruspostmenopausalosteoporosisosteoclastPBMCsbonemineraldensityBMDSAR-COV-2COVID-19Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ONO-5334
Cat. No.:
HY-108044
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.